Development and validation of a nomogram based on LASSO-logistic regression for predicting carotid atherosclerosis in patients with hypertension

基于LASSO-logistic回归的列线图的构建与验证,用于预测高血压患者的颈动脉粥样硬化。

阅读:2

Abstract

BACKGROUND AND OBJECTIVES: Carotid atherosclerosis (CAS) is increasingly prevalent among hypertensive patients. This study aims to develop a predictive nomogram for CAS in hypertensive population. METHODS: A total of 930 patients with hypertension were hospitalized in the Department of Cardiology of the Affiliated Hospital of Changzhou, Nanjing University of Chinese Medicine (August 2018-August 2024) formed the development cohort, categorized into CAS (156 individuals) and non-CAS (774 individuals) groups. Additionally, 398 hypertensive patients from the Department of Cardiology of the Second Affiliated Hospital of Soochow University served as the validation cohort (ratio 7:3), with 72 CAS individuals and 326 non-CAS individuals. LASSO regression initially identified key risk factors, followed by logistic regression for further analysis. The nomogram, constructed using the "rms" package in R 4.2.6, underwent internal validation via the 1,000 iterations of Bootstrap resampling. Model performance was evaluated through ROC curves, calibration curves, and decision curve analysis. RESULTS: Eight significant risk factors-Age, history of smoking (Smoke), history of diabetes mellitus (DM), course of hypertension (Course), physical activity (PA), body mass index (BMI), low-density lipoprotein (LDL), and uric acid (UA)-were identified (P < 0.05), among which DM was the most important influencing factor. The nomogram demonstrated strong predictive accuracy, with AUC values of 0.858 [95% CI (0.798, 0.918)] in the development cohort and 0.808 [95% CI (0.740, 0.876)] in the validation cohort. Calibration curves closely aligned with the ideal model, and decision curve analysis indicated optimal predictive performance within a probability threshold range of 0.050-0.960. CONCLUSIONS: This study presents a robust nomogram for assessing CAS risk in hypertensive patients, offering a valuable tool for clinical risk evaluation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。